Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A
J.R. Horton, Clayton B. Woodcock, Qin Chen, et al.
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 23, pp. 10588-10601
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Epigenetics-targeted drugs: current paradigms and future challenges
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 30
Overview of Recent Strategic Advances in Medicinal Chemistry
Gaochan Wu, Tong Zhao, Dongwei Kang, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 21, pp. 9375-9414
Open Access | Times Cited: 145
The emerging role of KDM5A in human cancer
Guan‐Jun Yang, Minghui Zhu, Xin‐Jiang Lu, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 83
Targeting Arginine Methyltransferase PRMT5 for Cancer Therapy: Updated Progress and Novel Strategies
Jiahong Zheng, Bang Li, Yingqi Wu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 8407-8427
Closed Access | Times Cited: 43
Emerging of lysine demethylases (KDMs): From pathophysiological insights to novel therapeutic opportunities
Sarder Arifuzzaman, Mst Reshma Khatun, R Khatun
Biomedicine & Pharmacotherapy (2020) Vol. 129, pp. 110392-110392
Open Access | Times Cited: 43
Targeting Epigenetic Regulators with Covalent Small-Molecule Inhibitors
Yi Zhang, Deqin Rong, Bingbing Li, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 12, pp. 7900-7925
Closed Access | Times Cited: 38
Sustainable click reactions: Use of greener reaction media in the synthesis of 1,2,3-triazoles
Luan A. Martinho, Carlos Kleber Z. Andrade
Tetrahedron (2024) Vol. 157, pp. 133964-133964
Closed Access | Times Cited: 5
Pharmacological inhibition of KDM5A for cancer treatment
Guan‐Jun Yang, Jia Wu, Miao Liang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 226, pp. 113855-113855
Closed Access | Times Cited: 28
Structural characterization of dicyanopyridine containing DNMT1-selective, non-nucleoside inhibitors
J.R. Horton, Sarath Pathuri, Kristen Wong, et al.
Structure (2022) Vol. 30, Iss. 6, pp. 793-802.e5
Open Access | Times Cited: 22
Discovery of a New-Generation S-Adenosylmethionine-Noncompetitive Covalent Inhibitor Targeting the Lysine Methyltransferase Enhancer of Zeste Homologue 2
Yi Zhang, Hong Yang, Bingbing Li, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 11, pp. 7629-7644
Closed Access | Times Cited: 13
Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy
Yuka Miyake, Yukihiro Itoh, Atsushi Hatanaka, et al.
Bioorganic & Medicinal Chemistry (2019) Vol. 27, Iss. 6, pp. 1119-1129
Open Access | Times Cited: 32
Targeting histone demethylase KDM5B for cancer treatment
Yun-Dong Fu, Ming-Jie Huang, Jia–Wen Guo, et al.
European Journal of Medicinal Chemistry (2020) Vol. 208, pp. 112760-112760
Closed Access | Times Cited: 30
The Clinically Used Iron Chelator Deferasirox Is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases
Martin Roatsch, Inga Hoffmann, Martine I. Abboud, et al.
ACS Chemical Biology (2019) Vol. 14, Iss. 8, pp. 1737-1750
Open Access | Times Cited: 27
Discovery of Novel Pyrazole-Based KDM5B Inhibitor TK-129 and Its Protective Effects on Myocardial Remodeling and Fibrosis
Kai Tang, Le-Min Jiao, Yuruo Qi, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 19, pp. 12979-13000
Closed Access | Times Cited: 16
Mechanistic QSAR modeling derived virtual screening, drug repurposing, ADMET and in - vitro evaluation to identify anticancer lead as lysine-specific demethylase 5a inhibitor
Rahul D. Jawarkar, Magdi E. A. Zaki, Sami A. Al‐Hussain, et al.
Journal of Biomolecular Structure and Dynamics (2024), pp. 1-31
Closed Access | Times Cited: 3
Development of JmjC-domain-containing histone demethylase (KDM2-7) inhibitors for cancer therapy
Lan Zhang, Yao Chen, Zhijia Li, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 5, pp. 103519-103519
Closed Access | Times Cited: 8
Extended Recognition of the Histone H3 Tail by Histone Demethylase KDM5A
Nektaria Petronikolou, James E. Longbotham, Danica Galonić Fujimori
Biochemistry (2020) Vol. 59, Iss. 5, pp. 647-651
Open Access | Times Cited: 20
Metalloprotein-Catalyzed Click Reaction for In Situ Generation of a Potent Inhibitor
Yuka Miyake, Yukihiro Itoh, Yoshinori Suzuma, et al.
ACS Catalysis (2020) Vol. 10, Iss. 10, pp. 5383-5392
Closed Access | Times Cited: 15
C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays
Yann‐Vaï Le Bihan, Rachel M. Lanigan, Butrus Atrash, et al.
European Journal of Medicinal Chemistry (2019) Vol. 177, pp. 316-337
Open Access | Times Cited: 13
Advances and Opportunities in Epigenetic Chemical Biology
Jenna N. Beyer, Nicole R. Raniszewski, George M. Burslem
ChemBioChem (2020) Vol. 22, Iss. 1, pp. 17-42
Closed Access | Times Cited: 12
Exploring Chemistry with Pyridine Derivatives

IntechOpen eBooks (2022)
Open Access | Times Cited: 7
Systematic Design of Adenosine Analogs as Inhibitors of a Clostridioides difficile-Specific DNA Adenine Methyltransferase Required for Normal Sporulation and Persistence
Jujun Zhou, J.R. Horton, Martina Menna, et al.
Journal of Medicinal Chemistry (2022) Vol. 66, Iss. 1, pp. 934-950
Open Access | Times Cited: 7
Covalent inhibitors meet epigenetics: new opportunities
Qiang Feng, Luoting Yu, Li Lu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 280, pp. 116951-116951
Closed Access | Times Cited: 1
Structural optimization of a lysine demethylase 5 inhibitor for improvement of its cellular activity
Mitsuhiro Terao, Yasunobu Yamashita, Yuri Takada, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 98, pp. 117579-117579
Closed Access | Times Cited: 2
Targeting Histone Acetyltransferase MOZ/KAT6A as a New Avenue for Hematological Tumor Therapy
Chongchen Zhou, Hai‐Liang Zhu, Yongtao Duan
Current Topics in Medicinal Chemistry (2020) Vol. 20, Iss. 5, pp. 333-335
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top